胰高血糖素样肽-1受体激动剂类药物疗效及在减重代谢外科中的应用
Efficacy of glucagon-like peptide-1 receptor agonists and its application in bariatric and meta-bolic surgery
王存川 1马庆阳 1陈文辉1
作者信息
- 1. 暨南大学附属第一医院肥胖与代谢病外科,广州 510630
- 折叠
摘要
目前,超重和肥胖症患病率增长迅速.减重代谢手术是治疗肥胖及相关合并症的有效手段,但仅少数肥胖症患者接受减重代谢手术,大部分患者选择药物减肥.新兴药物胰高糖素样肽-1受体激动剂(GLP-1RA)对超重和肥胖症患者疗效显著,可作为减重代谢手术的有益补充,给减重代谢外科带来深远影响.笔者全面回顾GLP-1RA类药物的应用进展,并深入阐述其在减重代谢外科中应用.
Abstract
At present,the prevalence of overweight and obesity is increasing rapidly.Baria-tric and metabolic surgery is an effective means to treat obesity and related comorbidities,but only a few obesity patients have received bariatric surgery,and most patients choose to accept drugs to lose weight.Glucagon-like peptide-1 receptor agonists(GLP-1RA),as an emerging drug,has a signi-ficant effect on overweight and obesity patients,and can be used as a beneficial supplement for bariatric surgery,which has a profound impact on bariatric surgery.Based on the relevant literature,the authors discuss the application and influence of GLP-1RA in bariatric and metabolic surgery.
关键词
肥胖症/减重代谢手术/减肥药物/胰高糖素样肽-1受体激动剂/应用Key words
Obesity/Bariatric metabolic surgery/Weight-loss drugs/Glucagon-like peptide-1 receptor agonist/Application引用本文复制引用
出版年
2024
NETL
NSTL
万方数据